The concept of 'borderline resectable' pancreatic cancer: Limited foundations and limited future?

John A Windsor, Savio George Barreto

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is traditionally treated by a surgery-first approach. The development and adoption of the concept of borderline resectable PDAC, which extends the role of surgery, is based on the proposition that neoadjuvant therapy (NAT) will increase the resection rate, margin negative rate and overall survival. There are a number of issues with this concept and a critical review of these suggests that it is based on limited foundations and likely has a limited future.

Original languageEnglish
Pages (from-to)189-193
Number of pages5
JournalJournal of Gastrointestinal Oncology
Volume8
Issue number1
DOIs
Publication statusPublished - 2017

Fingerprint Dive into the research topics of 'The concept of 'borderline resectable' pancreatic cancer: Limited foundations and limited future?'. Together they form a unique fingerprint.

  • Cite this